Single dose of chimeric dengue-2/Zika vaccine candidate protects mice and non-human primates against Zika virus

Whitney R. Baldwin, Holli A. Giebler, Janae L. Stovall, Ginger Young, Kelly J. Bohning, Hansi J. Dean, Jill A. Livengood and Claire Y.-H. Huang ()
Additional contact information
Whitney R. Baldwin: Arboviral Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention
Holli A. Giebler: Arboviral Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention
Janae L. Stovall: Arboviral Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention
Ginger Young: Takeda Vaccines Inc.
Kelly J. Bohning: Takeda Vaccines Inc.
Hansi J. Dean: Takeda Vaccines Inc.
Jill A. Livengood: Arboviral Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention
Claire Y.-H. Huang: Arboviral Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention

Nature Communications, 2021, vol. 12, issue 1, 1-15

Abstract: Abstract The development of a safe and effective Zika virus (ZIKV) vaccine has become a global health priority since the widespread epidemic in 2015-2016. Based on previous experience in using the well-characterized and clinically proven dengue virus serotype-2 (DENV-2) PDK-53 vaccine backbone for live-attenuated chimeric flavivirus vaccine development, we developed chimeric DENV-2/ZIKV vaccine candidates optimized for growth and genetic stability in Vero cells. These vaccine candidates retain all previously characterized attenuation phenotypes of the PDK-53 vaccine virus, including attenuation of neurovirulence for 1-day-old CD-1 mice, absence of virulence in interferon receptor-deficient mice, and lack of transmissibility in the main mosquito vectors. A single DENV-2/ZIKV dose provides protection against ZIKV challenge in mice and rhesus macaques. Overall, these data indicate that the ZIKV live-attenuated vaccine candidates are safe, immunogenic and effective at preventing ZIKV infection in multiple animal models, warranting continued development.

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-27578-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-27578-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-27578-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().